Notícias e Atividades da Deciphera Pharmaceuticals

Deciphera Pharmaceuticals pertence à ONO Pharmaceutical.

ONO Pharmaceutical é uma das ...

• TOB Iconic 10,000;
• Topix.

ONO Pharmaceutical é uma empresa listada sob o símbolo 4528 (JP).

ONO Pharmaceutical tem presença direta em 2 países.

Fusão, aquisição e financiamento envolvendo ONO Pharmaceutical.

• ONO Pharmaceutical adquiriu Deciphera Pharmaceuticals (publicado em 12 de junho de 2024).

Veja o organograma con seus 13 executivos principais

Biografias mais buscadas da Deciphera Pharmaceuticals

• Ryota Udagawa, Chief Executive Officer and President
• Toichi Takino, Director
• Masayuki Tanigawa, Director

Criar um alerta
para seguir os movimentos de executivos da Deciphera Pharmaceuticals.

ONO Pharmaceutical possui 1.834 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Eli Lilly (Estados Unidos).

Popular M&A news in Farmacêutica

• Imbria Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 58 milhões de dólares. (publicado em 10 de abril de 2025).
• Clario adquiriu NRx Pharmaceuticals (publicado em 18 de março de 2025).
• Knight Therapeutics has announced the acquisition of Paladin Labs  (publicado em 12 de março de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer da Adare Pharmaceuticals
• Seth Harrison - Chairman and Director da Braeburn Pharmaceuticals

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Deciphera Pharmaceuticals

• Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results | Deciphera Pharmaceuticals, Inc.
• Deciphera Pharmaceuticals, Inc. to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 4, 2022 | Deciphera Pharmaceuticals, Inc.
• Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Deciphera Pharmaceuticals, Inc.
• Deciphera Pharmaceuticals, Inc. Appoints Kelley Dealhoy as Chief Business Officer | Deciphera Pharmaceuticals, Inc.
• Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences | Deciphera Pharmaceuticals, Inc.
• Deciphera Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results | Deciphera Pharmaceuticals, Inc.
• Deciphera Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 4, 2022 | Deciphera Pharmaceuticals, Inc.
• Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares | Deciphera Pharmaceuticals, Inc.
• Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants | Deciphera Pharmaceuticals, Inc.
• Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants | Deciphera Pharmaceuticals, Inc.
• View more press releases Close

Redes sociais sobre Deciphera Pharmaceuticals

• Deciphera Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Deciphera Pharmaceuticals na LinkedIn, Twitter e YouTube